vs
Side-by-side financial comparison of HEARTLAND EXPRESS INC (HTLD) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
HEARTLAND EXPRESS INC is the larger business by last-quarter revenue ($179.4M vs $103.7M, roughly 1.7× Twist Bioscience Corp). HEARTLAND EXPRESS INC runs the higher net margin — -10.8% vs -29.4%, a 18.6% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -26.1%). Twist Bioscience Corp produced more free cash flow last quarter ($-34.8M vs $-44.2M).
Heartland Express is an American trucking company headquartered in North Liberty, Iowa. The company offers truckload shipping services across the United States.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
HTLD vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $179.4M | $103.7M |
| Net Profit | $-19.4M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -12.7% | -31.7% |
| Net Margin | -10.8% | -29.4% |
| Revenue YoY | -26.1% | 16.9% |
| Net Profit YoY | -949.2% | 3.4% |
| EPS (diluted) | $-0.24 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $179.4M | $103.7M | ||
| Q3 25 | $196.5M | — | ||
| Q2 25 | $210.4M | — | ||
| Q1 25 | $219.4M | — | ||
| Q4 24 | $242.6M | — | ||
| Q3 24 | $259.9M | — | ||
| Q2 24 | $274.8M | — | ||
| Q1 24 | $270.3M | — |
| Q4 25 | $-19.4M | $-30.5M | ||
| Q3 25 | $-8.3M | — | ||
| Q2 25 | $-10.9M | — | ||
| Q1 25 | $-13.9M | — | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-9.3M | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-15.1M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -12.7% | -31.7% | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | -5.9% | — | ||
| Q1 25 | -6.8% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | -5.3% | — |
| Q4 25 | -10.8% | -29.4% | ||
| Q3 25 | -4.2% | — | ||
| Q2 25 | -5.2% | — | ||
| Q1 25 | -6.3% | — | ||
| Q4 24 | -0.8% | — | ||
| Q3 24 | -3.6% | — | ||
| Q2 24 | -1.3% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | $-0.24 | $-0.50 | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.18 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.12 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.5M | $197.9M |
| Total DebtLower is stronger | $154.1M | — |
| Stockholders' EquityBook value | $755.3M | $456.1M |
| Total Assets | $1.2B | $638.1M |
| Debt / EquityLower = less leverage | 0.20× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.5M | $197.9M | ||
| Q3 25 | $32.7M | — | ||
| Q2 25 | $22.9M | — | ||
| Q1 25 | $23.9M | — | ||
| Q4 24 | $12.8M | — | ||
| Q3 24 | $30.7M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $23.8M | — |
| Q4 25 | $154.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $187.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $755.3M | $456.1M | ||
| Q3 25 | $775.6M | — | ||
| Q2 25 | $786.7M | — | ||
| Q1 25 | $807.7M | — | ||
| Q4 24 | $822.6M | — | ||
| Q3 24 | $825.7M | — | ||
| Q2 24 | $836.8M | — | ||
| Q1 24 | $848.8M | — |
| Q4 25 | $1.2B | $638.1M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.23× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.9M | $-24.8M |
| Free Cash FlowOCF − Capex | $-44.2M | $-34.8M |
| FCF MarginFCF / Revenue | -24.6% | -33.5% |
| Capex IntensityCapex / Revenue | 33.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-66.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.9M | $-24.8M | ||
| Q3 25 | $27.5M | — | ||
| Q2 25 | $21.0M | — | ||
| Q1 25 | $25.8M | — | ||
| Q4 24 | $37.8M | — | ||
| Q3 24 | $35.6M | — | ||
| Q2 24 | $40.0M | — | ||
| Q1 24 | $31.0M | — |
| Q4 25 | $-44.2M | $-34.8M | ||
| Q3 25 | $-12.2M | — | ||
| Q2 25 | $-12.8M | — | ||
| Q1 25 | $2.3M | — | ||
| Q4 24 | $-45.5M | — | ||
| Q3 24 | $24.6M | — | ||
| Q2 24 | $29.4M | — | ||
| Q1 24 | $26.3M | — |
| Q4 25 | -24.6% | -33.5% | ||
| Q3 25 | -6.2% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | -18.8% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 9.7% | — |
| Q4 25 | 33.0% | 9.6% | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 16.1% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 1.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTLD
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
